Immunization against viral diseases

Fields Virology: Sixth Edition

Volumn 1, Issue , 2013, Pages

  Graham, Barney S ^a   Crowe, James E ^b   Ledgerwood, Julie E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944475347     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (476)

1. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 1997;99(1):93-99.
2. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102(3 Pt 1):531-537.
3. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther 2002;13(1):3-13.
4. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356(19):1915-1927.
5. Ada GL, Leung KN, Ertl H. An analysis of effector T cell generation and function in mice exposed to influenza A or Sendai viruses. Immunol Rev 1981;58:5-24.
6. Afzal MA, Pickford AR, Forsey T, et al. The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates. J Gen Virol 1993;74(Pt 5):917-920.
7. Ahlers JD, Belyakov IM, Berzofsky JA. Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr Mol Med 2003;3(3):285-301.
8. Akahata W, Yang ZY, Andersen H, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 2010;16(3):334-338.
9. Akhrameyeva NV, Zhang P, Sugiyama N, et al. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. J Virol 2011;85(10):5036-5047.
10. Albrecht P, Ennis FA, Saltzman EJ, et al. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr 1977;91(5):715-718.
11. Aldovini A, Young RA. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 1991;351(6326):479-482.
12. Alwan WH, Record FM, Openshaw PJ. CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. Clin Exp Immunol 1992;88(3):527-536.
13. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292(5514):69-74.
14. Anderson JJ, Norden J, Saunders D, Toms GL, Scott R. Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection. J Gen Virol 1990;71:1561-1570.
15. Andino R, Silvera D, Suggett SD, et al. Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science 1994;265(5177):1448-1451.
16. Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998;244(2):365-396.
17. Armstrong SJ, Outlaw MC, Dimmock NJ. Morphological studies of the neutralization of influenza virus by IgM. J Gen Virol 1990;71(Pt 10):2313-2319.
18. Arness MK, Eckart RE, Love SS, et al. Myopericarditis following smallpox vaccination. Am J Epidemiol 2004;160(7):642-651.
19. Arnold JJ, Vignuzzi M, Stone JK, Andino R, Cameron CE. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J Biol Chem 2005;280(27):25706-25716.
20. Baden LR, Blattner WA, Morgan C, et al. Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV seronegative subjects. J Infect Dis 2011;204(10):1541-1549.
21. Baldridge JR, McGraw TS, Paoletti A, Buchmeier MJ. Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells. J Virol 1997;71(1):755-758.
22. Bansal GP, Hatfield JA, Dunn FE, et al. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis 1993;167(5):1034-1044.
23. Barbas III CF, Burton, D. R., Scott, J. K., and Silverman, G. J. Phage Display: A Laboratory Manual Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2001.
24. Barouch DH, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002;415(6869):335-339.
25. Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 2005;16(2):149-156.
26. Barouch DH, Yang ZY, Kong WP, et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 2005;79(14):8828-8834.
27. Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011;29(12):2272-2278.
28. Beasley RP, Hwang LY, Stevens CE, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983;3(2):135-141.
29. Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 1989;63(7):2941-2950.
30. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol 2005;6(4):353-360.
31. Belyakov IM, Earl P, Dzutsev A, et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A 2003;100(16):9458-9463.
32. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008;8(2):235-247.
33. Beran J, Hobzova L, Wertzova V, et al. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin 2010;6(7):578-584.
34. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002;298(5601):2199-2202.
35. Bernstein DI, Stanberry LR. Herpes simplex virus vaccines. Vaccine 1999;17(13-14):1681-1689.
36. Betts MR, Casazza JP, Koup RA. Monitoring HIV-specific CD8+ T cell responses by intracellular cytokine production. Immunol Lett 2001;79(1-2):117-125.
37. Billam P, Bonaparte KL, Liu J, et al. T Cell receptor clonotype influences epitope hierarchy in the CD8+ T cell response to respiratory syncytial virus infection. J Biol Chem 2011;286(6):4829-4841.
38. Bittle JL, Houghten RA, Alexander H, et al. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 1982;298(5869):30-33.
39. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998;79:1159-1167.
40. Blattman JN, Antia R, Sourdive DJ, et al. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J Exp Med 2002;195(5):657-664.
41. Bommakanti G, Citron MP, Hepler RW, et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A 2010;107(31):13701-13706.
42. Bomsel M, Tudor D, Drillet AS, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011;34(2):269-280.
43. Borisova GP, Berzins I, Pushko PM, et al. Recombinant core particles of hepatitis B virus exposing foreign antigenic determinants on their surface. FEBS Lett 1989;259(1):121-124.
44. Bostic JR, Brown KE, Young NS, Koenig S. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay. J Infect Dis 1999;179(3):619-626.
45. Bouchard MJ, Lam DH, Racaniello VR. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J Virol 1995;69(8):4972-4978.
46. Brecht H, Hammerling U, Rott R. Undisturbed release of influenza virus in the presence of univalent antineuraminidase antibodies. Virology 1971;46(2):337-343.
47. Brockman MA, Knipe DM. Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J Virol 2002;76(8):3678-3687.
48. Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996;70(9):6497-6501.
49. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372(9653):1881-1893.
50. Burns JW, Siadat-Pajouh M, Krishnaney AA, et al. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996;272(5258):104-107.
51. Burton DR, Desrosiers RC, Doms RW, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004;303 (5656):316.
52. Burton EA, Fink DJ, Glorioso JC. Gene delivery using herpes simplex virus vectors. DNA Cell Biol 2002;21(12):915-936.
53. Buser F. Side reaction to measles vaccination suggesting the Arthus phenomenon. N Engl J Med 1967;277(5):250-251.
54. Butman BT, Lizonova A, Brough DE, et al. Comprehensive characterization of the 293-ORF6 cell line. Dev Biol (Basel) 2006;123:225-233; discussion 265-226.
55. Calain P, Roux L. Generation of measles virus defective interfering particles and their presence in a preparation of attenuated live-virus vaccine. J Virol 1988;62(8):2859-2866.
56. Calarese DA, Lee HK, Huang CY, et al. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A 2005;102(38):13372-13377.
57. Campbell SA, Lin J, Dobrikova EY, Gromeier M. Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells. J Virol 2005;79(10):6281-6290.
58. Cannon MJ, Stott EJ, Taylor G, et al. Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. Immunology 1987;62(1):133-138.
59. Cannon MJ, Openshaw PJ, Askonas BA. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 1988;168:1163-1168.
60. Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997;238:198-211.
61. Carroll TD, Matzinger SR, Barro M, et al. Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone® in rhesus macaques. Vaccine 2011;29(5):931-940.
62. Casazza JP, Bowman K, Adzuku S, et al. Therapeutic vaccination expands and improves the function of the HIV-specific memory T cell repertoire. (submitted).
63. Castanon S, Marin MS, Martin-Alonso JM, et al. Immunization with potato plants expressing VP60 protein protects against rabbit hemorrhagic disease virus. J Virol 1999;73(5):4452-4455.
64. Castellino F, Boucher PE, Eichelberg K, et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 2000;191(11):1957-1964.
65. Catanzaro AT, Roederer M, Koup RA, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007;25(20):4085-4092.
66. Cecchini S, Negrete A, Virag T, et al. Evidence of prior exposure to human bocavirus as determined by a retrospective serological study of 404 serum samples from adults in the United States. Clin Vaccine Immunol 2009;16(5):597-604.
67. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009;101(19):1348-1355.
68. Chanock RM, Ludwig W, Heubner RJ, et al. Immunization by selective infection with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers. Jama 1966;195(6):445-452.
69. Chantler JK, Ford DK, Tingle AJ. Persistent rubella infection and rubella-associated arthritis. Lancet 1982;1(8285):1323-1325.
70. Chavan R, Marfatia KA, An IC, Garber DA, Feinberg MB. Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses. J Virol 2006;80(15):7676-7687.
71. Chen BJ, Leser GP, Morita E, et al. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 2007;81(13):7111-7123.
72. Chen X, Rock MT, Hammonds J, et al. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. J Virol 2005;79(9):5537-5547.
73. Cho HJ, Takabayashi K, Cheng PM, et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol 2000;18(5):509-514.
74. Choe H, Li W, Wright PL, et al. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 2003;114(2):161-170.
75. Chothia C, Lesk AM. Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 1987;196(4):901-917.
76. Chumakov KM, Norwood LP, Parker ML, et al. RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. J Virol 1992;66(2):966-970.
77. Chun TW, Justement JS, Moir S, et al. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies. Proc Natl Acad Sci U S A 2001;98(1):253-258.
78. Chung CY, Chen CY, Lin SY, et al. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine 2010;28(43):6951-6957.
79. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009;361(25):2424-2435.
80. Clarke BE, Sangar DV. Processing and assembly of foot-and-mouth disease virus proteins using subgenomic RNA. J Gen Virol 1988;69(Pt 9):2313-2325.
81. Clemens DL, Wolfinbarger JB, Mori S, Berry BD, Hayes SF, Bloom ME. Expression of Aleutian mink disease parvovirus capsid proteins by a recombinant vaccinia virus: self-assembly of capsid proteins into particles. J Virol 1992;66(5):3077-3085.
82. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998;177(5):1230-1246.
83. Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986;24(1):157-160.
84. Clements ML, Makhene MK, Karron RA, et al. Effective immunization with live attenuated influenza A virus can be achieved in early infancy. Pediatric Care Center. J Infect Dis 1996;173(1):44-51.
85. Coelingh KJ, Winter CC, Murphy BR, et al. Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J Virol 1986;60(1):90-96.
86. Coelingh KV, Winter CC. Naturally occurring human parainfluenza type 3 viruses exhibit divergence in amino acid sequence of their fusion protein neutralization epitopes and cleavage sites. J Virol 1990;64(3):1329-1334.
87. Collins JJ, Sackie DM, Johnson GR. Immunotherapy of murine leukemia. IX. The requirement for the Fc portion of antibody for successful passive serum therapy of Friend leukemia virus-induced disease. Virology 1983;126(1):259-266.
88. Connors M, Collins PL, Firestone CY, et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 1992;10(7):475-484.
89. Conrad ME, Lemon SM. Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin. J Infect Dis 1987;156(1):56-63.
90. Cooney EL, McElrath MJ, Corey L, et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A 1993;90(5):1882-1886.
91. Cooper CL, Angel JB, Seguin I, et al. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008;46(8):1310-1314.
92. Corbeil S, Seguin C, Trudel M. Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2. Vaccine 1996;14(6):521-525.
93. Correia BE, Ban YE, Holmes MA, et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 2010;18(9):1116-1126.
94. Cox JC, Coulter AR. Adjuvants-a classification and review of their modes of action. Vaccine 1997;15(3):248-256.
95. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011;29:621-663.
96. Crowe JE, Jr., Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 1995;13(9):847-855.
97. Crowe JE, Jr., Firestone CY, Murphy BR. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol 2001;167(7):3910-3918.
98. Cui Z, Mumper RJ. Genetic immunization using nanoparticles engineered from microemulsion precursors. Pharm Res 2002;19(7):939-946.
99. D'Aoust MA, Couture MM, Charland N, et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 2010;8(5):607-619.
100. Da Costa XJ, Jones CA, Knipe DM. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci U S A 1999;96(12):6994-6998.
101. Dagan R, Amir J, Mijalovsky A, et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 2000;19(11):1045-1052.
102. Dai B, Yang L, Yang H, et al. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci U S A 2009;106(48):20382-20387.
103. Dai K, Liu Y, Liu M, et al. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 2008;26(39):5062-5071.
104. Day PM, Kines RC, Thompson CD, et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 2010;8(3):260-270.
105. De Rosa SC, Lu FX, Yu J, et al. Vaccination in humans generates broad T cell cytokine responses. J Immunol 2004;173(9):5372-5380.
106. De Wit D, Olislagers V, Goriely S, et al. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. Blood 2004;103(3):1030-1032.
107. DiNapoli JM, Yang L, Samal SK, et al. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 2010;29(1):17-25.
108. Doherty PC. The tetramer transformation. J Immunol 2011;187(1):5-6.
109. Dollenmaier G, Mosier SM, Scholle F, Sharma N, McKnight KL, Lemon SM. Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic. Virology 2001;281(2):216-230.
110. Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol 2005;175(2):633-639.
111. Doores KJ, Burton DR. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 2010;84(20):10510-10521.
112. Dowd KA, Jost CA, Durbin AP, et al. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of west nile virus. PLoS Pathog 2011;7(6):e1002111.
113. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998;79:347-352.
114. Dryden KA, Wieland SF, Whitten-Bauer C, et al. Native hepatitis B virions and capsids visualized by electron cryomicroscopy. Mol Cell 2006;22(6):843-850.
115. Dubin G, Socolof E, Frank I, Friedman HM. Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J Virol 1991;65(12):7046-7050.
116. Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology 2006;344(1):230-239.
117. Durst M, Gissmann L, Ikenberg H, et al. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 1983;80(12):3812-3815.
118. Dwyer JM, Erlendsson K. Intraventricular gamma-globulin for the management of enterovirus encephalitis. Pediatr Infect Dis J 1988;7(5 Suppl):S30-33.
119. Eisenbarth SC, Colegio OR, O'Connor W, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008;453(7198):1122-1126.
120. Elliott SL, Pye S, Le T, et al. Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems. Vaccine 1999;17(15-16):2009-2019.
121. Enelow RI, Mohammed AZ, Stoler MH, et al. Structural and functional consequences of alveolar cell recognition by CD8(+) T lymphocytes in experimental lung disease. J Clin Invest 1998;102(9):1653-1661.
122. Ennis FA, Rook AH, Qi YH, et al. HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet 1981;2(8252):887-891.
123. Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 1984;2(8397):255-256.
124. Epstein SL, Misplon JA, Lawson CM, Subbarao EK, Connors M, Murphy BR. Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. J Immunol 1993;150:5484-5493.
125. Epstein SL, Kong WP, Misplon JA, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005;23(46-47):5404-5410.
126. Epstein SL. Prior H1N1 influenza infection and susceptibility of Cleveland family study participants during the H2N2 pandemic of 1957: An experiment of nature. J Infect Dis 2006;193:49-53.
127. Fang ZY, Limbach K, Tartaglia J, Hammonds J, Chen X, Spearman P. Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells. Virology 2001;291(2):272-284.
128. Felnerova D, Viret JF, Gluck R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004;15(6):518-529.
129. Fenner F, Henderson DA, Arita I, et al. Smallpox and its eradication Geneva: World Health Organization; 1988.
130. Ferguson M, Wood DJ, Minor PD. Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol 1993;74(Pt 4):685-690.
131. Flatz L, Hegazy AN, Bergthaler A, et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med 2010;16(3):339-345.
132. Flexner C, Murphy BR, Rooney JF, et al. Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen. Nature 1988;335(6187):259-262.
133. Flynn BJ, Kastenmuller K, Wille-Reece U, et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A 2011;108(17):7131-7136.
134. Flynn KJ, Belz GT, Altman JD, et al. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 1998;8(6):683-691.
135. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191(5):654-665.
136. Fouts TR, DeVico AL, Onyabe DY, et al. Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1. FEMS Immunol Med Microbiol 2003;37(2-3):129-134.
137. Fox J, Lennette E, Manso C, et al. Encephalitis in man following vaccination with 17D yellow fever virus. Am J Hygiene 1941;36:117-141.
138. Franco MA, Tin C, Greenberg HB. CD8+ T cells can mediate almost complete short-term and partial long- term immunity to rotavirus in mice. J Virol 1997;71(5):4165-4170.
139. Frey SE, Newman FK, Kennedy JS, et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine 2007;25(51):8562-8573.
140. Frolov I, Hoffman TA, Pragai BM, et al. Alphavirus-based expression vectors: strategies and applications. Proc Natl Acad Sci U S A 1996;93(21):11371-11377.
141. Fuerst TR, Earl PL, Moss B. Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol Cell Biol 1987;7(7):2538-2544.
142. Fujioka H, Emancipator SN, Aikawa M, et al. Immunocytochemical colocalization of specific immunoglobulin A with sendai virus protein in infected polarized epithelium. J Exp Med 1998;188(7):1223-1229.
143. Fulginiti VA, Eller JJ, Downie AW, et al. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 1967;202(12):1075-1080.
144. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. Jama 1998;280(6):527-532.
145. Gardner EM, Murasko DM. Age-related changes in Type 1 and Type 2 cytokine production in humans. Biogerontology 2002;3(5):271-290.
146. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356(19):1928-1943.
147. Georgescu MM, Balanant J, Macadam A, et al. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol 1997;71(10):7758-7768.
148. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005;191(5):666-677.
149. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364(5):401-411.
150. Glansbeek HL, Haagmans BL, te Lintelo EG, et al. Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus. J Gen Virol 2002;83(Pt 1):1-10.
151. Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Rotavirus vaccines: targeting the developing world. J Infect Dis 2005;192 Suppl 1:S160-166.
152. Goepfert PA, Horton H, McElrath MJ, et al. High-Dose Recombinant Canarypox Vaccine Expressing HIV-1 Protein, in Seronegative Human Subjects. J Infect Dis 2005;192(7):1249-1259.
153. Gokmen E, Bachier C, Raaphorst FM, et al. Ig heavy chain CDR3 size diversities are similar after conventional peripheral blood and ex vivo expanded hematopoietic cell transplants. Bone Marrow Transplant 2001;27(4):413-424.
154. Gorantla S, Santos K, Meyer V, et al. Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge. J Virol 2005;79(4):2124-2132.
155. Goriely S, Van Lint C, Dadkhah R, et al. A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells. J Exp Med 2004;199(7):1011-1016.
156. Gorny MK, Williams C, Volsky B, et al. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol 2002;76(18):9035-9045.
157. Gould SJ, Booth AM, Hildreth JE. The Trojan exosome hypothesis. Proc Natl Acad Sci U S A 2003;100(19):10592-10597.
158. Graham BS, Belshe RB, Clements ML, et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis 1992;166(2):244-252.
159. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993;151(4):2032-2040.
160. Graham BS, Matthews TJ, Belshe RB, et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis 1993;167(3):533-537.
161. Graham BS, Gorse GJ, Schwartz DH, et al. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. J Infect Dis 1994;170(4):782-786.
162. Graham BS, Keefer MC, McElrath MJ, et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med 1996;125(4):270-279.
163. Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006;194(12):1650-1660.
164. Graham BS, McElrath MJ, Keefer MC, et al. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One 2010;5(8):e11995.
165. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011;239(1):149-166.
166. Graham BS, Crowe JEJ. Tribute to David T. Karzon, MD and Robert M. Chanock, MD. Vaccine 2011 2011;29(21):3725-3727.
167. Graham BS, Walker C. Meeting the challenge of vaccine design to control HIV and other difficult viruses. In: Kaufmann SHE, Rouse BT, Sacks DL, eds. The Immune Response to Infection Washington, DC: ASM Press; 2011:559-570.
168. Graham MB, Braciale TJ. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 1997;186(12):2063-2068.
169. Gray GC, Goswami PR, Malasig MD, et al. Adult adenovirus infections: loss of orphaned vaccines precipitates military respiratory disease epidemics Clin Infect Dis 2000;31(3):663-670.
170. Gromeier M, Bossert B, Arita M, Nomoto A, Wimmer E. Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. J Virol 1999;73(2):958-964.
171. Grundner C, Li Y, Louder M, et al. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 2005;331(1):33-46.
172. Guillaume JC, Saiag P, Wechsler J, Lescs MC, Roujeau JC. Vaccinia from recombinant virus expressing HIV genes. Lancet 1991;337(8748):1034-1035.
173. Guirakhoo F, Zhang Z, Chambers TJ, et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against japanese encephalitis. Virology 1999;257(2):363-372.
174. Gutekunst RR, White RJ, Edmondson WP, et al. Immunization with live type 4 adenovirus: determination of infectious virus dose and protective effect of enteric infection. Am J Epidemiol 1967;86(2):341-349.
175. Guy B, Guirakhoo F, Barban V, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010;28(3):632-649.
176. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348(3):255-256.
177. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302(5644):415-419.
178. Haffar O, Garrigues J, Travis B, Moran P, Zarling J, Hu SL. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol 1990;64(6):2653-2659.
179. Haglund K, Leiner I, Kerksiek K, et al. High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. J Virol 2002;76(6):2730-2738.
180. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988;239(4839):476-481.
181. Hammon WM, Coriell LL, Wehrle PF, et al. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. J Am Med Assoc 1953;151(15):1272-1285.
182. Hammonds J, Chen X, Zhang X, et al. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines. Vaccine 2007;25(47):8036-8048.
183. Hanke T, Blanchard TJ, Schneider J, et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998;16(5):439-445.
184. Hanna SL, Pierson TC, Sanchez MD, Ahmed AA, Murtadha MM, Doms RW. N-linked glycosylation of west nile virus envelope proteins influences particle assembly and infectivity. J Virol 2005;79(21):13262-13274.
185. Hansen SG, Ford JC, Lewis MS, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011;473(7348):523-527.
186. Harrington PR, Yount B, Johnston RE, Davis N, Moe C, Baric RS. Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J Virol 2002;76(2):730-742.
187. Hart TK, Kirsh R, Ellens H, et al. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc Natl Acad Sci U S A 1991;88(6):2189-2193.
188. Hasenkrug KJ, Brooks DM, Dittmer U. Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol 1998;72(8):6559-6564.
189. Hawiger J. Noninvasive intracellular delivery of functional peptides and proteins. Curr Opin Chem Biol 1999;3(1):89-94.
190. Haynes BF, Fleming J, St Clair EW, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005;308(5730):1906-1908.
191. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007;449(7158):101-104.
192. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998;251(1):28-37.
193. Hodgson LA, Ludwig GV, Smith JF. Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors. Vaccine 1999;17(9-10):1151-1160.
194. Horvath B, Fornosi F. Excretion of SV40 virus after oral administration of contaminated polio vaccine. Acta Microbiol Hung 1964;11:271-275.
195. Hsu HM, Lu CF, Lee SC, Lin SR, Chen DS. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J Infect Dis 1999;179(2):367-370.
196. Hu SL, Travis BM, Garrigues J, et al. Processing, assembly, and immunogenicity of human immunodeficiency virus core antigens expressed by recombinant vaccinia virus. Virology 1990;179(1):321-329.
197. Huang Y, Yang ZY, Kong WP, Nabel GJ. Generation of synthetic severe acute respiratory syndrome coronavirus pseudoparticles: implications for assembly and vaccine production. J Virol 2004;78(22):12557-12565.
198. Hurwitz JL. Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections. Pediatr Infect Dis J 2008;27(10 Suppl):S126-128.
199. Hussey GD, Goddard EA, Hughes J, et al. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants. J Infect Dis 1996;173(6):1320-1326.
200. Ikizler MR, Wright PF. Thermostabilization of egg grown influenza viruses. Vaccine 2002;20(9-10):1393-1399.
201. Issel CJ, Horohov DW, Lea DF, et al. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol 1992;66(6):3398-3408.
202. Janeway CA. Use of concentrated human gamma globulin in the prevention and attenuation of measles. Bull NY Acad Med 1945;21:202-202.
203. Janeway CA, Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989;54 Pt 1:1-13.
204. Johnson PR, Feldman S, Thompson JM, et al. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986;154(1):121-127.
205. Johnson PR, Schnepp BC, Connell MJ, et al. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 2005;79(2):955-965.
206. Johnson PR, Schnepp BC, Zhang J, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009;15(8):901-906.
207. Johnston RE, Johnson PR, Connell MJ, et al. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. Vaccine 2005;23(42):4969-4979.
208. Jones D, Kroos N, Anema R, et al. High-level expression of recombinant IgG in the human cell line per.c6. Biotechnol Prog 2003;19(1):163-168.
209. Kaech SM, Hemby S, Kersh E, et al. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002;111(6):837-851.
210. Kalinke U, Bucher EM, Ernst B, et al. The role of somatic mutation in the generation of the protective humoral immune response against vesicular stomatitis virus. Immunity 1996;5(6):639-652.
211. Kallewaard NL, McKinney BA, Gu Y, et al. Functional maturation of the human antibody response to rotavirus. J Immunol 2008;180(6):3980-3989.
212. Kapikian AZ, Simonsen L, Vesikari T, et al. A Hexavalent Human Rotavirus-Bovine Rotavirus (UK) Reassortant Vaccine Designed for Use in Developing Countries and Delivered in a Schedule with the Potential to Eliminate the Risk of Intussusception. J Infect Dis 2005;192 Suppl 1:S22-29.
213. Karron RA, Belshe RB, Wright PF, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 2003;22(5):394-405.
214. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005;191(7):1093-1104.
215. Kast WM, Roux L, Curren J, et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A 1991;88(6):2283-2287.
216. Kaul TN, Welliver RC, Ogra PL. Development of antibody-dependent cell-mediated cytotoxicity in the respiratory tract after natural infection with respiratory syncytial virus. Infect Immun 1982;37(2):492-498.
217. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361(19):1838-1847.
218. Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011;3(85):85ra48.
219. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89(4):422-434.
220. Kim SK, Reed DS, Olson S, et al. Generation of mucosal cytotoxic T cells against soluble protein by tissue-specific environmental and costimulatory signals. Proc Natl Acad Sci U S A 1998;95(18):10814-10819.
221. Kim YC, Jarrahian C, Zehrung D, et al. Delivery systems for intradermal vaccination. Curr Top Microbiol Immunol 2012;351:77-112.
222. Kines RC, Thompson CD, Lowy DR, et al. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A 2009;106(48):20458-20463.
223. King JC, Jr., Cox MM, Reisinger K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 2009;27(47):6589-6594.
224. Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992;89(24):12180-12184.
225. Kobayashi T, Antar AA, Boehme KW, et al. A plasmid-based reverse genetics system for animal double-stranded RNA viruses. Cell Host Microbe 2007;1(2):147-157.
226. Kohl S. Role of antibody-dependent cellular cytotoxicity in defense against herpes simplex virus infections. Rev Infect Dis Jan-Feb 1991;13(1):108-114.
227. Konopka JL, Thompson JM, Whitmore AC, et al. Acute infection with venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challenge. J Virol 2009;83(23):12432-12442.
228. Kostense S, Raaphorst FM, Notermans DW, et al. Diversity of the T-cell receptor BV repertoire in HIV-1-infected patients reflects the biphasic CD4+ T-cell repopulation kinetics during highly active antiretroviral therapy. Aids 1998;12(18):F235-240.
229. Kostense S, Koudstaal W, Sprangers M, et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. Aids 2004;18(8):1213-1216.
230. Koup RA, Roederer M, Lamoreaux L, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010;5(2):e9015.
231. Kouri G, Guzman MG, Valdes L, et al. Reemergence of dengue in Cuba: a 1997 epidemic in Santiago de Cuba. Emerg Infect Dis 1998;4(1):89-92.
232. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347(21):1645-1651.
233. Krause JC, Tumpey TM, Huffman CJ, et al. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol 2010;84(6):3127-3130.
234. Kundig TM, Castelmur I, Bachmann MF, et al. Fewer protective cytotoxic T-cell epitopes than T-helper-cell epitopes on vesicular stomatitis virus. J Virol 1993;67(6):3680-3683.
235. Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393(6686):648-659.
236. Kwong PD, Doyle ML, Casper DJ, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002;420(6916):678-682.
237. Kwong PD, Wilson IA. HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 2009;10(6):573-578.
238. Lamparski HG, Metha-Damani A, Yao JY, et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002;270(2):211-226.
239. Langbeheim H, Arnon R, Sela M. Antiviral effect on MS-2 coliphage obtained with a synthetic antigen. Proc Natl Acad Sci U S A 1976;73(12):4636-4640.
240. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339(25):1797-1802.
241. Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 2001;75(13):6154-6165.
242. Ledgerwood JE, Graham BS. DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases. Hum Vaccin 2009;5(9):623-626.
243. Ledgerwood JE, Pierson TC, Hubka SA, et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 2011;203(10):1396-1404.
244. Lehner T, Bergmeier LA, Tao L, et al. Targeted lymph node immunization with simian immunodeficiency virus p27 antigen to elicit genital, rectal, and urinary immune responses in nonhuman primates. J Immunol 1994;153(4):1858-1868.
245. Lemiale F, Kong WP, Akyurek LM, et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 2003;77(18):10078-10087.
246. Lennon RG, Isacson P. Delayed dermal hypersensitivity following killed measles vaccine. Experience in 9-month-old infants. J Pediatr 1967;71(4):525-529.
247. Letvin NL, Rao SS, Montefiori DC, et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011;3(81):81ra36.
248. Levine B, Hardwick JM, Trapp BD, et al. Antibody-mediated clearance of alphavirus infection from neurons. Science 1991;254(5033):856-860.
249. Li M, Cripe TP, Estes PA, Lyon MK, Rose RC, Garcea RL. Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J Virol 1997;71(4):2988-2995.
250. Liao HX, Cianciolo GJ, Staats HF, et al. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF. Vaccine 2002;20(17-18):2396-2403.
251. Lin R, Tarr PE, Jones TC. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin Infect Dis 1995;21(6):1439-1449.
252. Little SR, Lynn DM, Ge Q, et al. Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci U S A 2004;101(26):9534-9539.
253. Locher CP, Putnam D, Langer R, Witt SA, Ashlock BM, Levy JA. Enhancement of a human immunodeficiency virus env DNA vaccine using a novel polycationic nanoparticle formulation. Immunol Lett 2003;90(2-3):67-70.
254. Lowe RS, Brown DR, Bryan JT, et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 1997;176(5):1141-1145.
255. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004;10(12):1359-1365.
256. Lubeck MD, Natuk R, Myagkikh M, et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 1997;3(6):651-658.
257. Luckow V, Summers M. Trends in the development of baculovirus expression vectors. Biotechnology 1988;6:47-55.
258. Lusky M. Good manufacturing practice production of adenoviral vectors for clinical trials. Hum Gene Ther 2005;16(3):281-291.
259. MacDonald GH, Johnston RE. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol 2000;74(2):914-922.
260. Mackett M, Archard LC. Conservation and variation in Orthopoxvirus genome structure. J Gen Virol 1979;45(3):683-701.
261. Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979;2(8154):1216-1217.
262. Manickan E, Francotte M, Kuklin N, et al. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells. J Virol 1995;69(8):4711-4716.
263. Marovich MA, Mascola JR, Eller MA, et al. Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. J Infect Dis 2002;186(9):1242-1252.
264. Martin JE, Pierson TC, Hubka S, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007;196(12):1732-1740.
265. Mascola JR. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 2002;20(15):1922-1925.
266. Mayr A, Hochstein-Mintzel V, Stickl H. Passage history, properties, and applicability of the attenuated vaccinia virus strain MVA. Infection 1975;3:6-14.
267. Mayr A, Stickl H, Muller HK, Danner K, Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl). Zentralbl Bakteriol [B] 1978;167(5-6):375-390.
268. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A 1992;89(15):6901-6905.
269. Mazanec MB, Kaetzel CS, Lamm ME, et al. Intracellular neutralization of Sendai and influenza viruses by IgA monoclonal antibodies. Adv Exp Med Biol 1995;371A:651-654.
270. McClain DJ, Pittman PR, Ramsburg HH, et al. Immunologic interference from sequential administration of live attenuated alphavirus vaccines. J Infect Dis 1998;177(3):634-641.
271. McCurdy LH, Rutigliano JA, Johnson TR, Chen M, Graham BS. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4. J Virol 2004;78(22):12471-12479.
272. McGinnes LW, Gravel KA, Finberg RW, et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol 2011;85(1):366-377.
273. McGuire TC, Adams DS, Johnson GC, Klevjer-Anderson P, Barbee DD, Gorham JR. Acute arthritis in caprine arthritis-encephalitis virus challenge exposure of vaccinated or persistently infected goats. Am J Vet Res 1986;47(3):537-540.
274. McLellan JS, Correia BE, Chen M, et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol 2011;409(5):853-866.
275. Mease PJ, Ochs HD, Wedgwood RJ. Successful treatment of echovirus meningoencephalitis and myositis-fasciitis with intravenous immune globulin therapy in a patient with X-linked agammaglobulinemia. N Engl J Med 1981;304(21):1278-1281.
276. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388(6640):394-397.
277. Meguro H, Kervina M, Wright PF. Antibody-dependent cell-mediated cytotoxicity against cells infected with respiratory syncytial virus: characterization of in vitro and in vivo properties. J Immunol 1979;122(6):2521-2526.
278. Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 1996;70(6):3930-3937.
279. Mercadal CM, Bouley DM, DeStephano D, Rouse BT. Herpetic stromal keratitis in the reconstituted scid mouse model. J Virol 1993;67(6):3404-3408.
280. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991;72:1031-1038.
281. Meyer HM, Jr., Hopps HE, Parkman PD, et al. Control of measles and rubella through use of attenuated vaccines. Am J Clin Pathol 1978;70(1 Suppl):128-135.
282. Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 2002;8(4):415-419.
283. Milstien JB, Lemon SM, Wright PF. Development of a more thermostable poliovirus vaccine. J Infect Dis 1997;175(Suppl 1):S247-S253.
284. Modlin JF, Halsey NA, Thoms ML, Meschievitz CK, Patriarca PA. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. J Infect Dis 1997;175 Suppl 1:S228-234.
285. Moghaddam A, Olszewska W, Wang B, et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006;12(8):905-907.
286. Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003;188(8):1213-1230.
287. Monsalvo AC, Batalle JP, Lopez MF, et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med 2011;17(2):195-199.
288. Montgomery DL, Shiver JW, Leander KR, et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 1993;12(9):777-783.
289. Morrison LA, Da Costa XJ, Knipe DM. Influence of mucosal and parenteral immunization with a replication- defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 1998;243(1):178-187.
290. Morrison TG. Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens. Future Virol 2010;5(5):545-554.
291. Mortimer EA, Jr., Lepow ML, Gold E, et al. Long-term follow-up of persons inadvertently inoculated with SV40 as neonates. N Engl J Med 1981;305(25):1517-1518.
292. Moser C, Metcalfe IC, Viret JF. Virosomal adjuvanted antigen delivery systems. Expert Rev Vaccines 2003;2(2):189-196.
293. Moskophidis D, Kioussis D. Contribution of virus-specific CD8+ cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. J Exp Med 1998;188(2):223-232.
294. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136(7):2348-2357.
295. Moss B, Flexner C. Vaccinia virus expression vectors. Annu Rev Immunol 1987;5:305-324.
296. Mozdzanowska K, Furchner M, Maiese K, Gerhard W. CD4+ T cells are ineffective in clearing a pulmonary infection with influenza type A virus in the absence of B cells. Virology 1997;239(1):217-225.
297. Mozdzanowska K, Maiese K, Furchner M, Gerhard W. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 1999;254(1):138-146.
298. Mueller S, Wimmer E. Introducing recombinant picornaviral genomes into cells. Cold Spring Harb Protoc 2011;2011(6).
299. Mullbacher A, Ebnet K, Blanden RV, et al. Granzyme A is critical for recovery of mice from infection with the natural cytopathic viral pathogen, ectromelia. Proc Natl Acad Sci U S A 1996;93(12):5783-5787.
300. Mumper RJ, Cui Z. Genetic immunization by jet injection of targeted pDNA-coated nanoparticles. Methods 2003;31(3):255-262.
301. Murphy BR, Prince GA, Walsh EE, et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986;24(2):197-202.
302. Murphy BR, Sotnikov A, Paradiso PR, et al. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 1989;7(6):533-540.
303. Murphy BR, Webster RG. Orthomyxoviruses. In: Fields BN, Knipe DM, Howley PM, et al., eds. Fields Virology Vol 1. Third ed. Philadelphia: Lippencott-Raven; 1996:1397-1445.
304. Murphy BR, Park EJ, Gottlieb P, Subbarao K. An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine 1997;15(12-13):1372-1378.
305. Murphy BR. Mucosal immunity to viruses. In: Ogra PL, Mestecky, J., Lamm, M.E., Strober, W., McGhee, J.R., Bienstock, J., ed. Mucosal Immunology Second ed: Academic Press, Inc; 1999:695-707.
306. Murphy BR, Morens DM, Simonsen L, Chanock RM, La Montagne JR, Kapikian AZ. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J Infect Dis 2003;187(8):1301-1308.
307. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011;29:587-619.
308. Murphy CG, Lucas WT, Means RE, et al. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol 2000;74(17):7745-7754.
309. Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci U S A 1996;93(2):934-939.
310. Nader P, Horwitz M, Rousseau J. Atypical exanthem following exposure to natural measles. Eleven cases in children previously inoculated with killed vaccine. J Pediatr 1968;72:22-28.
311. Nardelli-Haefliger D, Roden RB, Benyacoub J, et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997;65(8):3328-3336.
312. Nardelli B, Tam JP. The MAP system. A flexible and unambiguous vaccine design of branched peptides. Pharm Biotechnol 1995;6:803-819.
313. Nathanson N, Langmuir AD. The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963 [classical article]. Am J Epidemiol 1995;142(2):109-140; discussion 107-108.
314. Nchinda G, Kuroiwa J, Oks M, et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 2008;118(4):1427-1436.
315. Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. Cell Host Microbe 2011;9(5):355-361.
316. Neuzil KM, Johnson JE, Tang YW, et al. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 1997;15(5):525-532.
317. Nicholson KG, Abrams KR, Batham S, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011;11(2):91-101.
318. Niikura M, Takamura S, Kim G, et al. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology 2002;293(2):273-280.
319. Nkowane BM, Wassilak SG, Orenstein WA, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. Jama 1987;257(10):1335-1340.
320. Norrby E, Enders-Ruckle G, Meulen V. Differences in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus. J Infect Dis 1975;132(3):262-269.
321. Norrby E, Gollmar Y. Identification of measles virus-specific hemolysis-inihibiting antibodies separate from hemagglutination-inhibiting antibodies. Infect Immun 1975;11(2):231-239.
322. Norris PJ, Sumaroka M, Brander C, et al. Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones. J Virol 2001;75(20):9771-9779.
323. Norris PJ, Moffett HF, Yang OO, et al. Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4(+) T cells. J Virol 2004;78(16):8844-8851.
324. O'Hagan DT, Singh M, Ulmer JB. Microparticles for the delivery of DNA vaccines. Immunol Rev 2004;199:191-200.
325. O'Neill D, Bhardwaj N. Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy. Methods Mol Med 2005;109:97-112.
326. Ofek G, Guenaga FJ, Schief WR, et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A 2010;107(42):17880-17887.
327. Offit PA. The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis New Haven, CT: Yale University Press; 2007.
328. Oi VT, Vuong TM, Hardy R, et al. Correlation between segmental flexibility and effector function of antibodies. Nature 1984;307(5947):136-140.
329. Orentas RJ, Hildreth JE, Obah E, et al. Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 1990;248(4960):1234-1237.
330. Outlaw MC, Armstrong SJ, Dimmock NJ. Mechanisms of neutralization of influenza virus in tracheal epithelial and BHK cells vary according to IgG concentration. Virology 1990;178(2):478-485.
331. Outlaw MC, Dimmock NJ. Mechanisms of neutralization of influenza virus on mouse tracheal epithelial cells by mouse monoclonal polymeric IgA and polyclonal IgM directed against the viral haemagglutinin. J Gen Virol 1990;71(Pt 1):69-76.
332. Outlaw MC, Dimmock NJ. IgG neutralization of type A influenza viruses and the inhibition of the endosomal fusion stage of the infectious pathway in BHK cells. Virology 1993;195(2):413-421.
333. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352(22):2271-2284.
334. Palladino G, Mozdzanowska K, Washko G, Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 1995;69(4):2075-2081.
335. Palmenberg AC. In vitro synthesis and assembly of picornaviral capsid intermediate structures. J Virol 1982;44(3):900-906.
336. Pancera M, Wyatt R. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 2005;332(1):145-156.
337. Pantua HD, McGinnes LW, Peeples ME, Morrison TG. Requirements for the assembly and release of Newcastle disease virus-like particles. J Virol 2006;80(22):11062-11073.
338. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A 1996;93(21):11349-11353.
339. Parkman PD. Making vaccination policy: the experience with rubella. Clinical Infect Dis 1999;28(Suppl 2):S140-146.
340. Parr EL, Parr MB. Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2. J Virol 1998;72(6):5137-5145.
341. Parrino J, McCurdy LH, Larkin BD, et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 2007;25(8):1513-1525.
342. Pastoret PP, Brochier B. Epidemiology and control of fox rabies in Europe. Vaccine 1999;17(13-14):1750-1754.
343. Paust S, von Andrian UH. Natural killer cell memory. Nat Immunol 2011;131(6):500-508.
344. Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A. Human immunosenescence: is it infectious? Immunol Rev 2005;205:257-268.
345. Pedersen NC, Black JW. Attempted immunization of cats against feline infectious peritonitis, using avirulent live virus or sublethal amounts of virulent virus. Am J Vet Res 1983;44(2):229-234.
346. Pejchal R, Walker LM, Stanfield RL, et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A 2010;107(25):11483-11488.
347. Peng B, Wang LR, Gomez-Roman VR, et al. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol 2005;79(16):10200-10209.
348. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol 2004;4(8):648-655.
349. Pihlgren M, Schallert N, Tougne C, et al. Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life. Eur J Immunol 2001;31(3):939-946.
350. Piirainen L, Stenvik M, Roivainen M, Eskola J, Beuvery EC, Hovi T. Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: assessment of intestinal immunity with live challenge virus. Vaccine 1999;17(9-10):1084-1090.
351. Pimentel TA, Yan Z, Jeffers SA, et al. Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem Biol Drug Des 2009;73(1):53-61.
352. Pitisuttithum P, Nitayaphan S, Thongcharoen P, et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis 2003;188(2):219-227.
353. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194(12):1661-1671.
354. Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH, Peters CJ. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 1996;14(4):337-343.
355. Pletnev AG, Men R. Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. Proc Natl Acad Sci U S A 1998;95(4):1746-1751.
356. Polack FP, Auwaerter PG, Lee SH, et al. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med 1999;5(6):629-634.
357. Polack FP, Hoffman SJ, Crujeiras G, Griffin DE. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 2003;9(9):1209-1213.
358. Power UF, Plotnicky-Gilquin H, Huss T, et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 1997;230(2):155-166.
359. Prince GA, Horswood RL, Chanock RM. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 1985;55(3):517-520.
360. Publicover J, Ramsburg E, Rose JK. Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J Virol 2004;78(17):9317-9324.
361. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997;239(2):389-401.
362. Ramon G. Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum antidiptherique. Bull Soc Centr Med Vet 1925;101:227.
363. Ranasinghe C, Ramshaw IA. Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity. Expert Rev Vaccines 2009;8(9):1171-1181.
364. Ray P, Black S, Shinefield H, et al. Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team [see comments]. JAMA 1997;278(7):551-556.
365. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987;316:673-676.
366. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361(23):2209-2220.
367. Rezapkin GV, Fan L, Asher DM, Fibi MR, Dragunsky EM, Chumakov KM. Mutations in Sabin 2 Strain of Poliovirus and Stability of Attenuation Phenotype. Virology 1999;258(1):152-160.
368. Richman DD, Wrin T, Little SJ, et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003;100(7):4144-4149.
369. Roberts SR, Lichtenstein D, Ball LA, Wertz GW. The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons. J Virol 1994;68(7):4538-4546.
370. Robertson JS, Cook P, Nicolson C, Newman R, Wood JM. Mixed populations in influenza virus vaccine strains. Vaccine 1994;12(14):1317-1322.
371. Roivainen M, Piirainen L, Hovi T. Persistence and class-specificity of neutralizing antibody response induced by trypsin-cleaved type 3 poliovirus in mice. Vaccine 1993;11(7):713-717.
372. Rojas M, Donahue JP, Tan Z, Lin YZ. Genetic engineering of proteins with cell membrane permeability. Nat Biotechnol 1998;16(4):370-375.
373. Roldao A, Mellado MC, Castilho LR, et al. Virus-like particles in vaccine development. Expert Rev Vaccines 2010;9(10):1149-1176.
374. Romanowski B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccin 2011;7(2).
375. Rosario M, Hopkins R, Fulkerson J, et al. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. J Virol 2010;84(12):5898-5908.
376. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001;106(5):539-549.
377. Rothman AL, Ennis FA. Immunopathogenesis of Dengue hemorrhagic fever. Virology 1999;257(1):1-6.
378. Roy MJ, Wu MS, Barr LJ, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000;19(7-8):764-778.
379. Ruggeri FM, Johansen K, Basile G, Kraehenbuhl JP, Svensson L. Antirotavirus immunoglobulin A neutralizes virus in vitro after transcytosis through epithelial cells and protects infant mice from diarrhea. J Virol 1998;72(4):2708-2714.
380. Russell SM, Liew FY. T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin. Nature 1979;280(5718):147-148.
381. Sabin A. Properties and behavior of orally administered attenuated poliovirus vaccine. Jama 1957;164:1216-1223.
382. Sabin A, Boulger L. History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1973;1:115-118.
383. Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985;151(3):420-436.
384. Sakamoto S, Ide T, Tokiyoshi S, et al. Studies on the structures and antigenic properties of rabies virus glycoprotein analogues produced in yeast cells. Vaccine 1999;17(3):205-218.
385. Sakurai H, Williamson RA, Crowe JE, et al. Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines. J Virol 1999;73(4):2956-2962.
386. Sambandamurthy VK, Jacobs WR, Jr. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect 2005;7(5-6):955-961.
387. Sanders MT, Brown LE, Deliyannis G, Pearse MJ. ISCOM-based vaccines: the second decade. Immunol Cell Biol 2005;83(2):119-128.
388. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011;23(3):421-429.
389. Schelonka RL, Raaphorst FM, Infante D, Kraig E, Teale JM, Infante AJ. T cell receptor repertoire diversity and clonal expansion in human neonates. Pediatr Res 1998;43(3):396-402.
390. Scherle PA, Palladino G, Gerhard W. Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells. J Immunol 1992;148(1):212-217.
391. Schlesinger JJ, Foltzer M, Chapman S. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology 1993;192(1):132-141.
392. Schlom J, Hodge JW. The diversity of T-cell co-stimulation in the induction of antitumor immunity. Immunol Rev 1999;170:73-84.
393. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283(5403):857-860.
394. Schnepp BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 2003;77(6):3495-3504.
395. Scott R, de Landazuri MO, Gardner PS, Owen JJ. Human antibody-dependent cell-mediated cytotoxicity against target cells infected with respiratory syncytial virus. Clin Exp Immunol 1977;28(1):19-26.
396. Seaman MS, Xu L, Beaudry K, et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005;79(5):2956-2963.
397. Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003;4(9):835-842.
398. Selin LK, Lin MY, Kraemer KA, et al. Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity 1999;11(6):733-742.
399. Selin LK, Welsh RM. Plasticity of T cell memory responses to viruses. Immunity 2004;20(1):5-16.
400. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415(6869):331-335.
401. Sibbet G, Romero-Graillet C, Meneguzzi G, et al. alpha6 integrin is not the obligatory cell receptor for bovine papillomavirus type 4. J Gen Virol 2000;81(Pt 2):327-334.
402. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009;9(3):185-194.
403. Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ. More on RotaShield and Intussusception: The Role of Age at the Time of Vaccination. J Infect Dis 2005;192 Suppl 1:S36-43.
404. Singh RA, Wu L, Barry MA. Generation of genome-wide CD8 T cell responses in HLA-A*0201 transgenic mice by an HIV-1 ubiquitin expression library immunization vaccine. J Immunol 2002;168(1):379-391.
405. Snydman DR. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev Infect Dis 1990;12 Suppl 7:S839-848.
406. Song JM, Van Rooijen N, Bozja J, et al. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A 2011;108(2):757-761.
407. Spear GT, Takefman DM, Sullivan BL, et al. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus. Virology 1993;195(2):475-480.
408. Spriggs MK. One step ahead of the game: viral immunomodulatory molecules. Annu Rev Immunol 1996;14:101-130.
409. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347(21):1652-1661.
410. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl). Dtsch Med Wochenschr 1974;99(47):2386-2392.
411. Strasser R, Castilho A, Stadlmann J, et al. Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile. J Biol Chem 2009;284(31):20479-20485.
412. Strickler HD, Rosenberg PS, Devesa SS, et al. Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA 1998;279(4):292-295.
413. Sullivan NJ, Martin JE, Graham BS, et al. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009;7(5):393-400.
414. Sumida SM, Truitt DM, Lemckert AA, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005;174(11):7179-7185.
415. Tacket CO. Plant-derived vaccines against diarrheal diseases. Vaccine 2005;23(15):1866-1869.
416. Takafuji ET, Gaydos JC, Allen RG, et al. Simultaneous administration of live, enteric-coated adenovirus types 4, 7 and 21 vaccines: safety and immunogenicity. J Infect Dis 1979;140(1):48-53.
417. Tan M, Jiang X. The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. J Virol 2005;79(22):14017-14030.
418. Tan M, Huang P, Xia M, et al. Norovirus P particle, a novel platform for vaccine development and antibody production. J Virol 2011;85(2):753-764.
419. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356(6365):152-154.
420. Tang YW, Graham BS. Potential for directing appropriate responses to vaccines by cytokine manipulation. Clinical Immunotherapeutics 1996;5:327-333.
421. Tao T, Skiadopoulos MH, Durbin AP, Davoodi F, Collins PL, Murphy BR. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge. Vaccine 1999;17:1100-1108.
422. Taylor PM, Esquivel F, Askonas BA. Murine CD4+ T cell clones vary in function in vitro and in influenza infection in vivo. Int Immunol 1990;2(4):323-328.
423. Theiler M, Smith H. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J Exp Med 1939;65:767-787.
424. Tonkin DR, Jorquera P, Todd T, et al. Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. Vaccine 2010;28(18):3238-3246.
425. Topham DJ, Tripp RA, Doherty PC. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 1997;159(11):5197-5200.
426. Topham DJ, Doherty PC. Clearance of an influenza A virus by CD4+ T cells is inefficient in the absence of B cells. J Virol 1998;72(1):882-885.
427. Toran JL, Sanchez-Pulido L, Kremer L, del Real G, Valencia A, Martinez AC. Improvement in affinity and HIV-1 neutralization by somatic mutation in the heavy chain first complementarity-determining region of antibodies triggered by HIV-1 infection. Eur J Immunol 2001;31(1):128-137.
428. Townsend AR, Gotch FM, Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 1985;42(2):457-467.
429. Trapp S, von Einem J, Hofmann H, et al. Potential of equine herpesvirus 1 as a vector for immunization. J Virol 2005;79(9):5445-5454.
430. Treanor JJ, Betts RF. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Vaccine 1998;16(18):1756-1760.
431. Trill JJ, Shatzman AR, Ganguly S. Production of monoclonal antibodies in COS and CHO cells. Curr Opin Biotechnol 1995;6(5):553-560.
432. Valensi JP, Carlson JR, Van Nest GA. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 1994;153(9):4029-4039.
433. van Drunen Littel-van den Hurk S, Parker MD, Massie B, et al. Protection of cattle from BHV-1 infection by immunization with recombinant glycoprotein gIV. Vaccine 1993;11(1):25-35.
434. Van Kampen KR, Shi Z, Gao P, et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 2005;23(8):1029-1036.
435. Vasan S, Hurley A, Schlesinger SJ, et al. In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers. PLoS One 2011;6(5):e19252.
436. Vazquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. Jama 2004;291(7):851-855.
437. Vennema H, de Groot RJ, Harbour DA, et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol 1990;64(3):1407-1409.
438. Victoria JG, Wang C, Jones MS, et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol 2010;84(12):6033-6040.
439. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6(5):271-278.
440. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326(5950):285-289.
441. Wang BZ, Xu R, Quan FS, et al. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One 2010;5(11):e13972.
442. Wang C, Ge Q, Ting D, et al. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat Mater 2004;3(3):190-196.
443. Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998;282(5388):476-480.
444. Wang TT, Tan GS, Hai R, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 2010;107(44):18979-18984.
445. Warfield KL, Olinger G, Deal EM, et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005;175(2):1184-1191.
446. Waters TD, Anderson PS, Jr., Beebe GW, et al. Yellow fever vaccination, avian leukosis virus, and cancer risk in man. Science 1972;177(43):76-77.
447. Weber J, Cheinsong-Popov R, Callow D, et al. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine 1995;13(9):831-834.
448. Weitkamp JH, Lafleur BJ, Greenberg HB, et al. Natural evolution of a human virus-specific antibody gene repertoire by somatic hypermutation requires both hotspot-directed and randomly-directed processes. Hum Immunol 2005;66(6):666-676.
449. Werner GT, Jentzsch U, Metzger E, Simon J. Studies on Poxvirus infections in irradiated animals. Archives of Virology 1980;64:247-256.
450. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol 2005;174(12):7676-7683.
451. Williamson C, Morris L, Maughan MF, et al. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses 2003;19(2):133-144.
452. Wilson AD, Lovgren-Bengtsson K, Villacres-Ericsson M, Morein B, Morgan AJ. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines. Vaccine 1999;17(9-10):1282-1290.
453. Wolf M, Garcea RL, Grigorieff N, et al. Subunit interactions in bovine papillomavirus. Proc Natl Acad Sci U S A 2010;107(14):6298-6303.
454. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247(4949 Pt 1):1465-1468.
455. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. Jama 1993;270(24):2935-2939.
456. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008;453(7195):667-671.
457. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000;182(5):1331-1342.
458. Wu H, Pfarr DS, Tang Y, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 2005;350(1):126-144.
459. Wu X, Yang ZY, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010;329(5993):856-861.
460. Xin KQ, Jounai N, Someya K, et al. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 2005.
461. Xing L, Wang JC, Li TC, et al. Spatial configuration of hepatitis E virus antigenic domain. J Virol 2011;85(2):1117-1124.
462. Xu R, Ekiert DC, Krause JC, et al. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010;328(5976):357-360.
463. Yan H, Lamm ME, Bjorling E, Huang YT. Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model. J Virol 2002;76(21):10972-10979.
464. Yang OO, Kalams SA, Trocha A, et al. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997;71(4):3120-3128.
465. Yankauckas MA, Morrow JE, Parker SE, et al. Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol 1993;12(9):771-776.
466. Yokomori K, Baker SC, Stohlman SA, Lai MM. Hemagglutinin-esterase-specific monoclonal antibodies alter the neuropathogenicity of mouse hepatitis virus. J Virol 1992;66(5):2865-2874.
467. Yu X, Tsibane T, McGraw PA, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008;455(7212):532-536.
468. Yu Z, Karem KL, Kanangat S, Manickan E, Rouse BT. Protection by minigenes: a novel approach of DNA vaccines. Vaccine 1998;16(17):1660-1667.
469. Yuan L, Ward LA, Rosen BI, To TL, Saif LJ. Systematic and intestinal antibody-secreting cell responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease. J Virol 1996;70(5):3075-3083.
470. Zagury D. Anti-HIV cellular immunotherapy in AIDS. Lancet 1991;338(8768):694-695.
471. Zaia JA, Levin MJ, Preblud SR, et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983;147(4):737-743.
472. Zhang X, Brunner T, Carter L, et al. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997;185(10):1837-1849.
473. Zhou J, Sun XY, Stenzel DJ, et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185(1):251-257.
474. Zhou T, Georgiev I, Wu X, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010;329(5993):811-817.
475. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010;376(9744):895-902.
476. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2010;28:445-489.